Table 5 Clinical characteristics and features of patients with NMDAR positive grouped by the change of mRS
mRS change (ΔmRS) = mRS (pre) – mRS (post) | P value | ||
|---|---|---|---|
Parameter | No respond and worse (ΔmRS = 0) (-1,0) | Improvement (ΔmRS ≥ 1) (1,2) | |
N | 6 | 10 | |
Age (range) | 25.5 (17–35) | 28.5 (16–59) | 0.957 |
Gender (male %) | 33.3% | 50% | 0.633 |
Neoplasm (Ovarian teratoma or tumor) | 50% | 20% | 0.299 |
Serum antibody positive | 4 | 7 | 1.000 |
CSF antibody positive | 6 | 10 | 0.267 |
Both serum and CSF antibody positive | 4 | 7 | 1.000 |
Period from onset to DFPP (days) | 67.0 ± 69.6 | 99.4 ± 70.1 | 0.433 |
Plasma exchange volume of DFPP (ml/kg) | 47.5 ± 9.8 | 53.2 ± 12.2 | 0.325 |
DFPP circles (IQR) | 3.5 (3,4) | 3.5 (3,5) | 0.606 |
mRS pre (IQR) | 5 (3.75, 5) | 5 (4.75, 5) | 0.474 |
mRS post (IQR) | 5 (3.75, 5.25) | 4 (3.75, 4) | 0.041 |